Table 2 Patient characteristics and treatment outcome by FCGR2A and FCGR3A genotypes

Number of patients (%)

114 (22.6%)

261 (51.8%)

129 (25.6%)

241 (48.5%)

206 (41.4%)

50 (10.1%)

Age, median (range)

61 (27–74)

62 (24–75)

62 (30–75)

0.99^*

62 (24–75)

61 (29–75)

61 (35–75)

0.47^*

Sex, female/male

49/65

102/159

57/72

0.58^†

93/148

94/112

20/30

0.32^†

Location, colon/rectum

71/43

145/116

78/51

0.41^†

147/94

121/85

23/27

0.15^†

Metastatic sites, 1/>1

32/82

63/198

39/90

0.41^†

62/179

51/155

20/30

0.08^†

KRAS, wt/mutated

62/38

150/82

61/49

0.26^†

126/87

111/67

31/15

0.54^†

BRAF, wt/mutated

80/11

192/26

91/10

0.88^†

182/18

141/21

36/7

0.28^†

Treatment, FLOX/FLOX + cetuximab

33/81

90/171

49/80

0.34^†

79/162

75/131

15/35

0.58^†

Response; response/no-response

54/60

121/140

57/72

0.89^†

109/132

93/113

25/25

0.82^†

PFS (months), median

8.3

7.9

7.6

0.45^‡

7.9

7.6

8.4

0.76^‡

OS (months), median

21.9

19.8

18.2

0.42^‡

19.9

20.5

19.7

0.77^‡